Patient reported outcomes analysis
During clinical interview, patients with CM diagnosis reported a
reduction in HIT-6 baseline score 69.88 (5.61) to 64.98 (7.81)
after receiving 3 doses (-4.90; 95% CI: -2.67,-7.13; p<0.01)
and 61.94 (9.93) after 6 doses of erenumab (-6.75; 95% CI:
-3.03,-10.47; p<0.01) (Figure 4A ). Likewise, patients
treated with galcanezumab also reported a reduction in HIT-6 score from
68.91 (4.93) to 64.09 (9.01) after receiving 3 doses (-5.15; 95% CI:
-2.70,-7.60; p<0.01) and 63.46 (9.40) after receiving 6 doses
(7.06; 95% CI: -2.73,-11.39; p<0.01) (Figure 4B ).
Analogous results were observed in patients diagnosed with EM .
Erenumab reduced HIT-6 score from 66.92 (6.56) at baseline to
58.16 (12.15) after the administration of 3 doses (-8.76; 95% CI:
-3.92,-13.60; p<0.01) and to 56.83 (12.10) after 6 doses
(-9.89; 95% CI: -4.07,-15.71; p<0.01) (Figure 4C ).
Galcanezumab reduced HIT-6 score from 67.87 (3.53) at baseline to 59.27
(9.65) after the administration of 3 doses (-8.64; 95% CI:
-4.86,-12.42; p<0.01) and to 60.73 (11.24) after 6 doses
(-7.94; 95% CI: -3.32,-12.56; p<0.01) (Figure 4D ).
Regarding MIDAS , patients with CM treated with erenumab
experienced a reduction from baseline 86.23 (50.06) to 61.04 (45.55)
after the administration of 3 doses (-25.19; 95% CI: -13.65,-36.73;
p<0.01) and to 39.84 (43.61) after 6 doses (-36.79; 95% CI:
-18.99,-54.59; p<0.01) (Figure 5A ). Similarly,
patients treated with galcanezumab also reported a reduction from of
110.55 (54.40) to 73.31 (56.12) after the administration of 3 doses
(-35.82; 95% CI: -15.98,-55.66; p<0.01) and to 68.08 (39.99)
after 6 doses (-38.73; 95% CI: -12.36,-65.46; p<0.01)
(Figure 5B ).
Likewise, patients diagnosed with EM treated with erenumab
reported a reduction in MIDAS from baseline 61.62 (42.44) to
37.77 (58.45) after the administration of 3 doses (-23.85; 95% CI:
-1.47,-46.23; p<0.01) and to 20.17 (17.05) after 6 doses
(-33.44; 95% CI: -10.98,-55.90; p<0.01) (Figure 5C ).
Galcanezumab reduced HIT-6 score from 75.96 (41.57) at baseline to 27.95
(27.74) after the administration of 3 doses (-48.96; 95% CI:
-25.86,-72.06; p<0.01) and to 26.14 (24.94) after 6 doses
(-47.29; 95% CI: -19.04,-75.54; p<0.01) (Figure 5D ).
Additionally, erenumab reduced VAS in patients with CMfrom baseline 8.85 (1.15) to 7.59 (2.02) after the administration of 3
doses (-1.26; 95% CI: -0.70,-1.82; p<0.01) and to 6.56 (2.33)
after 6 doses (-2.22; 95% CI: -1.82,-2.62; p<0.01)
(Figure 6A ). Galcanezumab also reduced from baseline 8.41
(0.96) to 7.24 (1.84) after the administration of 3 doses (-1.09; 95%
CI: -0.54,-1.64; p<0.01) and to 7.00 (2.58) and 6 doses
(-1.00; 95% CI: -0.19,-1.81; p<0.01) (Figure 6B ).
Moreover, patients with EM also experienced a reduction inVAS from baseline 8.85 (1.29) to 7.31 (2.29) after the
administration of 3 doses (-1.54; 95% CI: -0.62,-2.46;
p<0.01) and to 6.58 (2.55) after 6 doses of erenumab (-2.21;
95% CI: -1.09,-3.33; p<0.01) (Figure 6C ).
Galcanezumab also diminished VAS from baseline 8.41 (0.96) to 7.24
(1.84) after the administration of 3 doses (1.24 reduction; 95% CI
0.55-1.93; p<0.01) and to 7.00 (2.58) and 6 doses (-1.23; 95%
CI: 0.25,-2.81; p<0.01) (Figure 6D ).